FDA fast tracks J&J’s nipocalimab to reduce risk of FNAIT
Johnson & Johnson has announced the FDA’s fast track approval of nipocalimab for treating FNAIT in alloimmunized pregnant persons.
News
-
-
UNITY fetal antigen test to be used in phase 3 nipocalimab trial
BillionToOne will allow its UNITY fetal antigen test to be used to test patients in the phase 3 trial evaluating the safety and efficacy of nipocalimab.
- Why finding others with an FNAIT diagnosis is so important
- How I explain my baby’s FNAIT diagnosis to others
- How FNAIT influenced my family planning
From the
FNAIT Ambassador
FNAIT Ambassador
Learn more about FNAIT
Sign up for the latest news, perspectives, and information about FNAIT.
